Trinity Biotech projects it reached Adjusted EBITDA1 -positive operations during Q2 2025 and expects to be Adjusted EBITDA1 positive going forward, reflecting continued strong execution on its ...

Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc ...

Review Trinity Biotech PLC ADR (TRIB:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

DUBLIN, July 01, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...

Trinity Biotech’s patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech ...

GlobeNewswire Jun 24, 2025, 5:00:38 AM Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update GlobeNewswire May 15, 2025, 1:00:39 PM ...

View the latest Trinity Biotech PLC ADR (TRIB) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Trinity Biotech PLC ADR Annual cash flow by MarketWatch. View TRIB net cash flow, operating cash flow, operating expenses and cash dividends.

Trinity Biotech plc (NASDAQ: TRIB) recently provided an update on its continued development of its glucose biosensor technology. Earlier this year, the company was granted a European patent for a ...

Trinity Biotech Plc is listed on the CBOE trading with ticker code TRIB.US. It has a market capitalisation of -, with approximately 0.00 shares in issue. Over the last year, Trinity Biotech Plc ...